Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma

LONDON, April 10, 2014 /PRNewswire/ --

The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:

http://www.investor-edge.com/1006-register

Shares in AVANIR Pharmaceuticals Inc. reported a trading volume of 1.74 million shares, as compared with its three months average volume of 2.28 million shares. The stock ended the day at an intra-day high of $3.87, up 8.40%, and at an intraday range of $3.59 and $3.87. AVANIR Pharmaceuticals Inc.'s shares have gained 11.85% in the previous three trading sessions and 15.18% on YTD basis, while the same has declined 13.42% in the last one month. The stock is trading below its 50-day and 200-day moving averages of $3.90 and $4.22, respectively. Moreover, the stock has a Relative Strength Index (RSI) of 42.29. Sign up today to read free research on AVNR at:

http://www.investor-edge.com/1006-AVNR-10Apr2014.pdf

Zoetis Inc.'s stock finished the session 0.31% lower at $29.06. A total of 3.63 million shares were traded, which is below its three months average volume of 4.97 million shares. The stock fluctuated between $28.77 and $29.22 during the session. The company's shares traded at a PE ratio of 21.15. Zoetis Inc.'s stock has fallen by 0.89% in the previous three trading sessions, 4.97% in the last one month and 11.10% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $29.96 and $30.98, respectively. Further, the stock has an RSI of 42.88. Sign up today to read free research on ZTS at:

http://www.investor-edge.com/1006-ZTS-10Apr2014.pdf

On Wednesday, shares in Salix Pharmaceuticals Ltd gained 3.71% to close the day at $105.76. The stock recorded a trading volume of 0.98 million shares as compared with its three months average volume of 1.10 million shares. The stock oscillated between $101.83 and $105.99 during the trading session. Shares of the company traded at a PE ratio of 48.23. Salix Pharmaceuticals Ltd's shares have advanced 3.46% in the previous three trading sessions and 17.59% on YTD basis, while the same has declined 3.73% in the last one month. The stock is trading above its 50-day and 200-day moving averages of $105.12 and $83.55, respectively. Moreover, the stock has an RSI of 43.74. Sign up today to read free research on SLXP at:

http://www.investor-edge.com/1006-SLXP-10Apr2014.pdf

Jazz Pharmaceuticals PLC's stock recorded a trading volume of 1.32 million shares, as compared with its three months average volume of 1.27 million shares. The stock ended the day at $136.91, up 5.24%, after vacillating between $130.86 and $136.97. The company's shares traded at a PE ratio of 35.52. Jazz Pharmaceuticals PLC's shares have gained 7.97% in the previous three trading sessions and 8.18% on YTD basis, while the same has fallen by 11.81% in the last one month. The company's stock is trading below its 50-day moving average. Jazz Pharmaceuticals PLC's 50-day moving average of $151.15 is above its 200-day moving average of $110.51. Furthermore, shares of the company have an RSI of 37.72. Sign up today to read free research on JAZZ at:

http://www.investor-edge.com/1006-JAZZ-10Apr2014.pdf

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.investor-edge.com/

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED